. 2017 Jun; 77(12):1313-1336.
doi: 10.1007/s40265-017-0774-5.

Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies

Tessa G Steenbruggen 1 Mette S van Ramshorst 1 Marleen Kok 1 Sabine C Linn 1 Carolien H Smorenburg 1 Gabe S Sonke 2 
  • PMID: 28616845
  •     233 References
  •     9 citations


In the last decade, the systemic treatment approach for patients with early breast cancer has partly shifted from adjuvant treatment to neoadjuvant treatment. Systemic treatment administration started as a 'one size fits all' approach but is currently customized according to each breast cancer subtype. Systemic treatment in a neoadjuvant setting is at least as effective as in an adjuvant setting and has several additional advantages. First, it enables response monitoring and provides prognostic information; second, it downstages the tumor, allowing for less extensive surgery, improved cosmetic outcomes, and reduced postoperative complications such as lymphedema; and third, it enables early development of new treatment strategies by using pathological complete remission as a surrogate outcome of event-free and overall survival. In this review we give an overview of the current standard of neoadjuvant systemic treatment strategies for the three main subtypes of breast cancer: hormone receptor-positive, triple-negative, and human epidermal growth factor receptor 2-positive. Additionally, we summarize drugs that are under investigation for use in the neoadjuvant setting.

Dual Block with Lapatinib and Trastuzumab Versus Single-Agent Trastuzumab Combined with Chemotherapy as Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Meta-analysis of Randomized Trials.
Matteo Clavarezza, Matteo Puntoni, +4 authors, Andrea DeCensi.
Clin Cancer Res, 2016 May 04; 22(18). PMID: 27140927
Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer.
L S Rigter, C E Loo, +11 authors, S Rodenhuis.
Br J Cancer, 2013 Oct 24; 109(12). PMID: 24149178    Free PMC article.
Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial.
S Loibl, C Jackisch, +19 authors, investigators of the German Breast Group (GBG) and the Arbeitsgemeinschaft Gynäkologische Onkologie—Breast (AGO-B) study groups.
Ann Oncol, 2016 Nov 11; 28(3). PMID: 27831502
ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer.
Katharina Feldinger, Daniele Generali, +15 authors, Anthony Kong.
Oncotarget, 2014 Jun 24; 5(16). PMID: 24952873    Free PMC article.
Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study).
Yoshie Hasegawa, Hirokazu Tanino, +15 authors, JONIE Study Group.
PLoS One, 2015 Dec 04; 10(12). PMID: 26633806    Free PMC article.
High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials.
Donald A Berry, Naoto T Ueno, +21 authors, Taner Demirer.
J Clin Oncol, 2011 Jul 20; 29(24). PMID: 21768471    Free PMC article.
Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.
Davide Mauri, Nicholas Pavlidis, John P A Ioannidis.
J Natl Cancer Inst, 2005 Feb 03; 97(3). PMID: 15687361
Highly Cited.
Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer.
Ruud van der Noll, Serena Marchetti, +6 authors, Jan H M Schellens.
Br J Cancer, 2015 Jul 17; 113(3). PMID: 26180927    Free PMC article.
The history and future of targeting cyclin-dependent kinases in cancer therapy.
Uzma Asghar, Agnieszka K Witkiewicz, Nicholas C Turner, Erik S Knudsen.
Nat Rev Drug Discov, 2015 Jan 31; 14(2). PMID: 25633797    Free PMC article.
Highly Cited. Review.
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.
Jürg Bernhard, Weixiu Luo, +18 authors, Barbara A Walley.
Lancet Oncol, 2015 Jun 21; 16(7). PMID: 26092816    Free PMC article.
Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.
A S Coates, E P Winer, +6 authors, Panel Members.
Ann Oncol, 2015 May 06; 26(8). PMID: 25939896    Free PMC article.
Highly Cited.
Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer.
Edith A Perez, Vera J Suman, +10 authors, Robert B Jenkins.
J Clin Oncol, 2011 Nov 02; 29(34). PMID: 22042958    Free PMC article.
Highly Cited.
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
Xavier Pivot, Gilles Romieu, +18 authors, PHARE trial investigators.
Lancet Oncol, 2013 Jun 15; 14(8). PMID: 23764181
Highly Cited.
Characteristics and treatment of human epidermal growth factor receptor 2 positive breast cancer: 43,485 cases from the National Cancer Database treated in 2010 and 2011.
Brigid K Killelea, Anees B Chagpar, Nina R Horowitz, Donald R Lannin.
Am J Surg, 2016 Oct 23; 213(2). PMID: 27769548
BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance.
Rinske Drost, Peter Bouwman, +13 authors, Jos Jonkers.
Cancer Cell, 2011 Dec 17; 20(6). PMID: 22172724
Highly Cited.
Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.
Robert Coleman, David Cameron, +13 authors, AZURE investigators.
Lancet Oncol, 2014 Jul 19; 15(9). PMID: 25035292
Highly Cited.
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
José Baselga, Mario Campone, +18 authors, Gabriel N Hortobagyi.
N Engl J Med, 2011 Dec 14; 366(6). PMID: 22149876    Free PMC article.
Highly Cited.
Trastuzumab emtansine for HER2-positive advanced breast cancer.
Sunil Verma, David Miles, +12 authors, EMILIA Study Group.
N Engl J Med, 2012 Oct 02; 367(19). PMID: 23020162    Free PMC article.
Highly Cited.
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.
Michael Untch, Sibylle Loibl, +18 authors, Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study Group.
Lancet Oncol, 2012 Jan 20; 13(2). PMID: 22257523
Highly Cited.
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study.
Global Burden of Disease Cancer Collaboration, Christina Fitzmaurice, +183 authors, Mohsen Naghavi.
JAMA Oncol, 2016 Dec 06; 3(4). PMID: 27918777    Free PMC article.
Highly Cited.
Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women.
E Comen, M Davids, +3 authors, M Robson.
Breast Cancer Res Treat, 2011 Mar 12; 129(1). PMID: 21394499    Free PMC article.
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†.
M Piccart, G N Hortobagyi, +17 authors, J Baselga.
Ann Oncol, 2014 Sep 19; 25(12). PMID: 25231953    Free PMC article.
Highly Cited.
Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib.
Anneleen Daemen, Denise M Wolf, +12 authors, Laura J van't Veer.
Breast Cancer Res Treat, 2012 Aug 10; 135(2). PMID: 22875744    Free PMC article.
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
Olivia Pagani, Meredith M Regan, +32 authors, International Breast Cancer Study Group.
N Engl J Med, 2014 Jun 03; 371(2). PMID: 24881463    Free PMC article.
Highly Cited.
PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment.
Angel Guerrero-Zotano, Ingrid A Mayer, Carlos L Arteaga.
Cancer Metastasis Rev, 2016 Nov 30; 35(4). PMID: 27896521
Highly Cited. Review.
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), R Peto, +15 authors, K Pritchard.
Lancet, 2011 Dec 14; 379(9814). PMID: 22152853    Free PMC article.
Highly Cited.
Hallmarks of 'BRCAness' in sporadic cancers.
Nicholas Turner, Andrew Tutt, Alan Ashworth.
Nat Rev Cancer, 2004 Oct 29; 4(10). PMID: 15510162
Highly Cited. Review.
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
Martine J Piccart-Gebhart, Marion Procter, +30 authors, Herceptin Adjuvant (HERA) Trial Study Team.
N Engl J Med, 2005 Oct 21; 353(16). PMID: 16236737
Highly Cited.
Breast-cancer adjuvant therapy with zoledronic acid.
Robert E Coleman, Helen Marshall, +17 authors, AZURE Investigators.
N Engl J Med, 2011 Oct 15; 365(15). PMID: 21995387
Highly Cited.
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.
Gunter von Minckwitz, Andreas Schneeweiss, +23 authors, Michael Untch.
Lancet Oncol, 2014 May 06; 15(7). PMID: 24794243
Highly Cited.
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Luca Gianni, Wolfgang Eiermann, +17 authors, Jose Baselga.
Lancet, 2010 Feb 02; 375(9712). PMID: 20113825
Highly Cited.
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
W Fraser Symmans, Caimiao Wei, +17 authors, Gabriel N Hortobagyi.
J Clin Oncol, 2017 Jan 31; 35(10). PMID: 28135148    Free PMC article.
Highly Cited.
Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy.
John Stagg, Sherene Loi, +5 authors, Mark J Smyth.
Proc Natl Acad Sci U S A, 2011 Apr 13; 108(17). PMID: 21482773    Free PMC article.
Highly Cited.
Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer.
Rowan T Chlebowski, Kathy Pan, Nananda F Col.
Breast Cancer Res Treat, 2016 Oct 28; 161(2). PMID: 27785653
Systematic Review.
A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer.
Mothaffar F Rimawi, Sabina B Aleixo, +10 authors, C Kent Osborne.
Clin Breast Cancer, 2014 Dec 30; 15(2). PMID: 25537159
Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.
Harry D Bear, Gong Tang, +18 authors, Norman Wolmark.
Lancet Oncol, 2015 Aug 15; 16(9). PMID: 26272770    Free PMC article.
Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
Bruno Coudert, Jean-Yves Pierga, +17 authors, Alina Berriolo-Riedinger.
Lancet Oncol, 2014 Dec 03; 15(13). PMID: 25456368
Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers.
E H Lips, L Mulder, +6 authors, P M Nederlof.
Br J Cancer, 2013 Apr 06; 108(10). PMID: 23558900    Free PMC article.
Highly Cited.
Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer.
Ian E Krop, Thomas M Suter, +8 authors, Luca Gianni.
J Clin Oncol, 2015 Feb 26; 33(10). PMID: 25713436    Free PMC article.
Adjuvant trastuzumab in HER2-positive breast cancer.
Dennis Slamon, Wolfgang Eiermann, +21 authors, Breast Cancer International Research Group.
N Engl J Med, 2011 Oct 14; 365(14). PMID: 21991949    Free PMC article.
Highly Cited.
Biosimilars for the Treatment of Cancer: A Systematic Review of Published Evidence.
Ira Jacobs, Reginald Ewesuedo, Sadiq Lula, Charles Zacharchuk.
BioDrugs, 2017 Jan 13; 31(1). PMID: 28078656    Free PMC article.
Systematic Review.
Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype.
Claudette E Loo, Marieke E Straver, +4 authors, Kenneth G A Gilhuijs.
J Clin Oncol, 2011 Jan 12; 29(6). PMID: 21220595
Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy.
Marieke A Vollebergh, Esther H Lips, +9 authors, Sabine C Linn.
Breast Cancer Res, 2014 Jun 03; 16(3). PMID: 24887359    Free PMC article.
New and developing chemical pharmacotherapy for treating hormone receptor-positive/HER2-negative breast cancer.
Rossella Martinello, Sofia Genta, +5 authors, Filippo Montemurro.
Expert Opin Pharmacother, 2016 Oct 21; 17(16). PMID: 27646965
Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer.
Chellappagounder Thangavel, Jeffry L Dean, +5 authors, Erik S Knudsen.
Endocr Relat Cancer, 2011 Mar 04; 18(3). PMID: 21367843    Free PMC article.
Highly Cited.
Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure.
Mila Donker, Marieke E Straver, +7 authors, Marie-Jeanne T F D Vrancken Peeters.
Ann Surg, 2014 Apr 20; 261(2). PMID: 24743607
Pathological complete response and accelerated drug approval in early breast cancer.
Tatiana M Prowell, Richard Pazdur.
N Engl J Med, 2012 Jun 01; 366(26). PMID: 22646508
Highly Cited.
Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial.
E Alba, J Albanell, +12 authors, A Lluch.
Br J Cancer, 2014 Jan 25; 110(5). PMID: 24457911    Free PMC article.
Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial.
Hope S Rugo, Abhijit Barve, +22 authors, Heritage Study Investigators.
JAMA, 2016 Dec 06; 317(1). PMID: 27918780
Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: A meta-analysis.
Zeeshan Jawa, Ruth M Perez, +5 authors, Yang Shi.
Medicine (Baltimore), 2016 Nov 20; 95(44). PMID: 27858859    Free PMC article.
A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.
Cynthia X Ma, Cesar Sanchez, +10 authors, Matthew J Ellis.
Clin Cancer Res, 2016 Jan 20; 22(11). PMID: 26783290    Free PMC article.
Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study.
W Eiermann, S Paepke, +10 authors, Letrozole Neo-Adjuvant Breast Cancer Study Group.
Ann Oncol, 2002 Feb 02; 12(11). PMID: 11822750
Highly Cited.
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Luca Gianni, Tadeusz Pienkowski, +17 authors, Pinuccia Valagussa.
Lancet Oncol, 2011 Dec 14; 13(1). PMID: 22153890
Highly Cited.
Optimum duration of neoadjuvant letrozole to permit breast conserving surgery.
Robert Carpenter, Julie C Doughty, +7 authors, Anthony I Skene.
Breast Cancer Res Treat, 2014 Feb 25; 144(3). PMID: 24562823
Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
Heikki Joensuu, Pirkko-Liisa Kellokumpu-Lehtinen, +17 authors, Henrik Lindman.
J Clin Oncol, 2011 Nov 23; 30(1). PMID: 22105826
Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70).
Claus Hanusch, Andreas Schneeweiss, +14 authors, Gunter von Minckwitz.
Clin Cancer Res, 2015 Apr 01; 21(13). PMID: 25825476
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), C Davies, +11 authors, R Peto.
Lancet, 2011 Aug 02; 378(9793). PMID: 21802721    Free PMC article.
Highly Cited.
Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling.
Frankie Ann Holmes, Virginia Espina, +11 authors, Joyce A O'Shaughnessy.
BMC Res Notes, 2013 Dec 07; 6. PMID: 24304724    Free PMC article.
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.
Lucia Del Mastro, Sabino De Placido, +22 authors, Gruppo Italiano Mammella (GIM) investigators.
Lancet, 2015 Mar 06; 385(9980). PMID: 25740286
Molecular portraits of human breast tumours.
C M Perou, T Sørlie, +15 authors, D Botstein.
Nature, 2000 Aug 30; 406(6797). PMID: 10963602
Highly Cited.
Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
Sara A Hurvitz, Fabrice Andre, +17 authors, Dennis Slamon.
Lancet Oncol, 2015 Jun 21; 16(7). PMID: 26092818
Highly Cited.
Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole.
William R Miller, Alexey Larionov.
Breast Cancer Res, 2010 Jul 22; 12(4). PMID: 20646288    Free PMC article.
Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancer.
S Chia, S Gandhi, +8 authors, S F Dent.
Curr Oncol, 2015 Feb 17; 22(1). PMID: 25684987    Free PMC article.
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
Gabriel N Hortobagyi, Salomon M Stemmer, +34 authors, Joyce O'Shaughnessy.
N Engl J Med, 2016 Nov 03; 375(18). PMID: 27717303
Highly Cited.
Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.
Denise A Yardley, Shinzaburo Noguchi, +17 authors, Hope S Rugo.
Adv Ther, 2013 Oct 26; 30(10). PMID: 24158787    Free PMC article.
Highly Cited.
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
D J Slamon, G M Clark, +3 authors, W L McGuire.
Science, 1987 Jan 09; 235(4785). PMID: 3798106
Highly Cited.
HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues.
Marilyn A Owens, Bruce C Horten, Moacyr M Da Silva.
Clin Breast Cancer, 2004 May 14; 5(1). PMID: 15140287
Highly Cited.
Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions.
Komal Jhaveri, Stefan O Ochiana, +8 authors, Gabriela Chiosis.
Expert Opin Investig Drugs, 2014 Mar 29; 23(5). PMID: 24669860    Free PMC article.
Highly Cited. Review.
Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade.
Philipp Müller, Matthias Kreuzaler, +12 authors, Alfred Zippelius.
Sci Transl Med, 2015 Nov 27; 7(315). PMID: 26606967
Highly Cited.
Adaptive Randomization of Neratinib in Early Breast Cancer.
John W Park, Minetta C Liu, +41 authors, I-SPY 2 Investigators.
N Engl J Med, 2016 Jul 15; 375(1). PMID: 27406346    Free PMC article.
Highly Cited.
Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).
Joanne L Blum, Patrick J Flynn, +19 authors, Norman Wolmark.
J Clin Oncol, 2017 Apr 12; 35(23). PMID: 28398846    Free PMC article.
Highly Cited.
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
Edward H Romond, Edith A Perez, +22 authors, Norman Wolmark.
N Engl J Med, 2005 Oct 21; 353(16). PMID: 16236738
Highly Cited.
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.
David Cameron, Martine J Piccart-Gebhart, +16 authors, Herceptin Adjuvant (HERA) Trial Study Team.
Lancet, 2017 Feb 22; 389(10075). PMID: 28215665    Free PMC article.
Highly Cited.
PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer.
Robert J Crowder, Chanpheng Phommaly, +14 authors, Matthew J Ellis.
Cancer Res, 2009 Apr 16; 69(9). PMID: 19366795    Free PMC article.
Population-based analysis of breast cancer treatment by intrinsic sub-type in Manitoba, Canada.
Elizabeth Hammond, Emma Shu, +11 authors, Marshall Pitz.
Cancer Epidemiol, 2016 Oct 23; 45. PMID: 27770672
Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network.
Nancy U Lin, Ann Vanderplas, +7 authors, Jane C Weeks.
Cancer, 2012 May 01; 118(22). PMID: 22544643    Free PMC article.
Highly Cited.
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.
Fabrice André, Ruth O'Regan, +20 authors, Luca Gianni.
Lancet Oncol, 2014 Apr 20; 15(6). PMID: 24742739
Highly Cited.
The immune system and response to HER2-targeted treatment in breast cancer.
Giampaolo Bianchini, Luca Gianni.
Lancet Oncol, 2014 Feb 01; 15(2). PMID: 24480556
Highly Cited. Review.
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
José Baselga, Vladimir Semiglazov, +17 authors, Hope S Rugo.
J Clin Oncol, 2009 Apr 22; 27(16). PMID: 19380449
Highly Cited.
Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study.
Stephen E Jones, Rufus Collea, +16 authors, Joyce O'Shaughnessy.
Lancet Oncol, 2013 Sep 07; 14(11). PMID: 24007746
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.
Lisa A Carey, Donald A Berry, +15 authors, Clifford A Hudis.
J Clin Oncol, 2015 Nov 04; 34(6). PMID: 26527775    Free PMC article.
Highly Cited.
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.
José Baselga, Sandra M Swain.
Nat Rev Cancer, 2009 Jun 19; 9(7). PMID: 19536107
Highly Cited. Review.
Preoperative chemotherapy for women with operable breast cancer.
J S D Mieog, J A van der Hage, C J H van de Velde.
Cochrane Database Syst Rev, 2007 Apr 20; (2). PMID: 17443564    Free PMC article.
Systematic Review.
Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.
Luisa Bonilla, Irit Ben-Aharon, +3 authors, Salomon M Stemmer.
J Natl Cancer Inst, 2010 Nov 26; 102(24). PMID: 21098761    Free PMC article.
Systematic Review.
Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44).
B Gerber, S Loibl, +18 authors, German Breast Group Investigators.
Ann Oncol, 2013 Oct 19; 24(12). PMID: 24136883
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.
Antonio Llombart-Cussac, Javier Cortés, +13 authors, Aleix Prat.
Lancet Oncol, 2017 Feb 28; 18(4). PMID: 28238593
Highly Cited.
Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies.
Matteo Lambertini, Marcello Ceppi, +20 authors, MIG and GIM study groups.
Eur J Cancer, 2016 Dec 13; 71. PMID: 27951450
Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial.
Paul E Goss, Ian E Smith, +17 authors, TEACH investigators.
Lancet Oncol, 2012 Dec 14; 14(1). PMID: 23234763
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Luca Gianni, Tadeusz Pienkowski, +17 authors, Pinuccia Valagussa.
Lancet Oncol, 2016 May 18; 17(6). PMID: 27179402
Highly Cited.
Decreased androgen receptor expression is associated with distant metastases in patients with androgen receptor-expressing triple-negative breast carcinoma.
Lisa M Sutton, Dengfeng Cao, +4 authors, Yan Peng.
Am J Clin Pathol, 2012 Sep 27; 138(4). PMID: 23010705
An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients.
M A Vollebergh, E H Lips, +15 authors, S C Linn.
Ann Oncol, 2010 Dec 08; 22(7). PMID: 21135055    Free PMC article.
Repeated observation of breast tumor subtypes in independent gene expression data sets.
Therese Sorlie, Robert Tibshirani, +13 authors, David Botstein.
Proc Natl Acad Sci U S A, 2003 Jun 28; 100(14). PMID: 12829800    Free PMC article.
Highly Cited.
Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.
A Goldhirsch, W C Wood, +4 authors, Panel members.
Ann Oncol, 2011 Jun 29; 22(8). PMID: 21709140    Free PMC article.
Highly Cited.
Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis.
Kristine R Broglio, Melanie Quintana, +11 authors, Donald A Berry.
JAMA Oncol, 2016 Feb 26; 2(6). PMID: 26914222
The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis.
Elizabeth Anderson.
Breast Cancer Res, 2002 Sep 12; 4(5). PMID: 12223124    Free PMC article.
Twenty years of anti-HER2 therapy-associated cardiotoxicity.
Noam F Pondé, Matteo Lambertini, Evandro de Azambuja.
ESMO Open, 2016 Nov 16; 1(4). PMID: 27843627    Free PMC article.
Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial.
Marco Venturini, Lucia Del Mastro, +11 authors, Paolo Bruzzi.
J Natl Cancer Inst, 2005 Dec 08; 97(23). PMID: 16333028
Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression.
Harold J Burstein, Christina Lacchetti, +9 authors, Jennifer J Griggs.
J Clin Oncol, 2016 Feb 18; 34(14). PMID: 26884586
Highly Cited. Systematic Review.
AKT activation predicts outcome in breast cancer patients treated with tamoxifen.
Tove Kirkegaard, Caroline J Witton, +4 authors, John M S Bartlett.
J Pathol, 2005 Aug 10; 207(2). PMID: 16088978
Whole-genome analysis informs breast cancer response to aromatase inhibition.
Matthew J Ellis, Li Ding, +56 authors, Elaine R Mardis.
Nature, 2012 Jun 23; 486(7403). PMID: 22722193    Free PMC article.
Highly Cited.
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
Peter C Fong, David S Boss, +12 authors, Johann S de Bono.
N Engl J Med, 2009 Jun 26; 361(2). PMID: 19553641
Highly Cited.
Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer.
D G Evans, A Howell, +3 authors, D M Eccles.
J Med Genet, 2011 Jun 10; 48(8). PMID: 21653198
SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer.
George T Budd, William E Barlow, +17 authors, Gabriel N Hortobagyi.
J Clin Oncol, 2014 Nov 26; 33(1). PMID: 25422488    Free PMC article.
Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.
L G Presta, H Chen, +5 authors, N Ferrara.
Cancer Res, 1997 Oct 23; 57(20). PMID: 9377574
Highly Cited.
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Patricia Cortazar, Lijun Zhang, +34 authors, Gunter von Minckwitz.
Lancet, 2014 Feb 18; 384(9938). PMID: 24529560
Highly Cited. Review.
A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.
Ingrid A Mayer, Vandana G Abramson, +11 authors, Carlos L Arteaga.
Clin Cancer Res, 2016 Apr 30; 23(1). PMID: 27126994    Free PMC article.
Highly Cited.
Targeting the androgen receptor in triple-negative breast cancer.
Ayca Gucalp, Tiffany A Traina.
Curr Probl Cancer, 2016 Nov 07; 40(2-4). PMID: 27816190    Free PMC article.
HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.
Shanu Modi, Alison Stopeck, +12 authors, Clifford Hudis.
Clin Cancer Res, 2011 May 12; 17(15). PMID: 21558407
Highly Cited.
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
Aman U Buzdar, Nuhad K Ibrahim, +17 authors, Gabriel N Hortobagyi.
J Clin Oncol, 2005 Mar 02; 23(16). PMID: 15738535
Highly Cited.
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.
Fatima Cardoso, Laura J van't Veer, +32 authors, MINDACT Investigators.
N Engl J Med, 2016 Aug 25; 375(8). PMID: 27557300
Highly Cited.
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
Andrew Tutt, Mark Robson, +12 authors, James Carmichael.
Lancet, 2010 Jul 09; 376(9737). PMID: 20609467
Highly Cited.
PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes.
H R Ali, S-E Glont, +10 authors, C Caldas.
Ann Oncol, 2015 Apr 22; 26(7). PMID: 25897014
Highly Cited.
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
Ian E Smith, Mitch Dowsett, +8 authors, IMPACT Trialists Group.
J Clin Oncol, 2005 Jul 07; 23(22). PMID: 15998903
Highly Cited.
Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis.
Laura M Spring, Arjun Gupta, +5 authors, Aditya Bardia.
JAMA Oncol, 2016 Jul 02; 2(11). PMID: 27367583    Free PMC article.
Highly Cited. Systematic Review.
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).
A Schneeweiss, S Chia, +10 authors, J Cortés.
Ann Oncol, 2013 May 25; 24(9). PMID: 23704196
Highly Cited.
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.
Cornelia Liedtke, Chafika Mazouni, +10 authors, Lajos Pusztai.
J Clin Oncol, 2008 Feb 06; 26(8). PMID: 18250347
Highly Cited.
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Michael Gnant, Brigitte Mlineritsch, +20 authors, C Marth.
N Engl J Med, 2009 Feb 14; 360(7). PMID: 19213681
Highly Cited.
Biomarkers of Response and Resistance to DNA Repair Targeted Therapies.
Elizabeth H Stover, Panagiotis A Konstantinopoulos, Ursula A Matulonis, Elizabeth M Swisher.
Clin Cancer Res, 2016 Sep 30; 22(23). PMID: 27678458
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2015 Jul 28; 386(10001). PMID: 26211824
Highly Cited.
It is not time to stop progesterone receptor testing in breast cancer.
R Colomer, M Beltran, +6 authors, E Ciruelos.
J Clin Oncol, 2005 Jun 01; 23(16). PMID: 15923595
Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research.
Valentina Zambonin, Alessandro De Toma, +10 authors, Emilio Bria.
Expert Opin Biol Ther, 2017 Jan 31; 17(4). PMID: 28133971
BRCA1-like profile predicts benefit of tandem high dose epirubicin-cyclophospamide-thiotepa in high risk breast cancer patients randomized in the WSG-AM01 trial.
Philip C Schouten, Oleg Gluz, +13 authors, Frederik Marme.
Int J Cancer, 2016 Mar 08; 139(4). PMID: 26946057
Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer.
S Muenst, A R Schaerli, +9 authors, S D Soysal.
Breast Cancer Res Treat, 2014 May 21; 146(1). PMID: 24842267    Free PMC article.
Highly Cited.
Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.
Ayca Gucalp, Sara Tolaney, +20 authors, Translational Breast Cancer Research Consortium (TBCRC 011).
Clin Cancer Res, 2013 Aug 24; 19(19). PMID: 23965901    Free PMC article.
Highly Cited.
Capecitabine in Combination with Standard (Neo)Adjuvant Regimens in Early Breast Cancer: Survival Outcome from a Meta-Analysis of Randomized Controlled Trials.
Ze-Chun Zhang, Qi-Ni Xu, Sui-Ling Lin, Xu-Yuan Li.
PLoS One, 2016 Oct 16; 11(10). PMID: 27741288    Free PMC article.
Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.
Stephen Jones, Frankie Ann Holmes, +17 authors, Michael A Savin.
J Clin Oncol, 2009 Feb 11; 27(8). PMID: 19204201
Highly Cited.
Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer.
Philipp Kiewe, Stephan Hasmüller, +9 authors, Michael Untch.
Clin Cancer Res, 2006 May 19; 12(10). PMID: 16707606
Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients--a phase II trial.
Duveken B Y Fontein, Ayoub Charehbili, +11 authors, Cornelis J H van de Velde.
Eur J Cancer, 2014 Jun 28; 50(13). PMID: 24970786
Breast cancers with a BRCA1-like DNA copy number profile recur less often than expected after high-dose alkylating chemotherapy.
Philip C Schouten, Frederik Marmé, +6 authors, Sabine C Linn.
Clin Cancer Res, 2014 Dec 07; 21(4). PMID: 25480832
Theoretical concepts and the emerging role of taxanes in adjuvant therapy.
L Norton.
Oncologist, 2001 May 11; 6 Suppl 3. PMID: 11346683
Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.
Edith A Perez, Edward H Romond, +13 authors, Norman Wolmark.
J Clin Oncol, 2014 Oct 22; 32(33). PMID: 25332249    Free PMC article.
Highly Cited.
Preclinical profile of the HER2-targeting ADC SYD983/SYD985: introduction of a new duocarmycin-based linker-drug platform.
Wim Dokter, Ruud Ubink, +20 authors, Marco Timmers.
Mol Cancer Ther, 2014 Sep 06; 13(11). PMID: 25189543
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.
G Valabrega, F Montemurro, M Aglietta.
Ann Oncol, 2007 Jan 19; 18(6). PMID: 17229773
Highly Cited. Review.
Trastuzumab containing regimens for early breast cancer.
Lorenzo Moja, Ludovica Tagliabue, +4 authors, Roberto D'Amico.
Cochrane Database Syst Rev, 2012 Apr 20; (4). PMID: 22513938    Free PMC article.
Highly Cited. Systematic Review.
Perturbations of the AKT signaling pathway in human cancer.
Deborah A Altomare, Joseph R Testa.
Oncogene, 2005 Nov 17; 24(50). PMID: 16288292
Highly Cited. Review.
The clonal and mutational evolution spectrum of primary triple-negative breast cancers.
Sohrab P Shah, Andrew Roth, +56 authors, Samuel Aparicio.
Nature, 2012 Apr 13; 486(7403). PMID: 22495314    Free PMC article.
Highly Cited.
NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.
Cynthia X Ma, Feng Gao, +31 authors, Matthew J Ellis.
Clin Cancer Res, 2017 Mar 09; 23(15). PMID: 28270497    Free PMC article.
Highly Cited.
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.
Aron Goldhirsch, Richard D Gelber, +23 authors, Herceptin Adjuvant (HERA) Trial Study Team.
Lancet, 2013 Jul 23; 382(9897). PMID: 23871490
Highly Cited.
CD8⁺ cytotoxic T cell and FOXP3⁺ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes.
Fangfang Liu, Ronggang Lang, +7 authors, Li Fu.
Breast Cancer Res Treat, 2011 Jul 01; 130(2). PMID: 21717105
Highly Cited.
Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer.
Joseph A Sparano, Fengmin Zhao, +7 authors, Nancy E Davidson.
J Clin Oncol, 2015 Jun 17; 33(21). PMID: 26077235    Free PMC article.
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.
Sara M Tolaney, William T Barry, +16 authors, Eric P Winer.
N Engl J Med, 2015 Jan 08; 372(2). PMID: 25564897    Free PMC article.
Highly Cited.
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.
Luca Gianni, Wolfgang Eiermann, +17 authors, Jose Baselga.
Lancet Oncol, 2014 Mar 25; 15(6). PMID: 24657003
Highly Cited.
Neoadjuvant Bevacizumab plus Chemotherapy versus Chemotherapy Alone to Treat Non-Metastatic Breast Cancer: A Meta-Analysis of Randomised Controlled Trials.
Li Cao, Guang-yu Yao, +3 authors, Chang-sheng Ye.
PLoS One, 2015 Dec 31; 10(12). PMID: 26717149    Free PMC article.
An update on PARP inhibitors--moving to the adjuvant setting.
Amir Sonnenblick, Evandro de Azambuja, Hatem A Azim, Martine Piccart.
Nat Rev Clin Oncol, 2014 Oct 08; 12(1). PMID: 25286972
Highly Cited. Review.
Tamoxifen-citrate counteracts the antitumor effects of cytotoxic drugs in vitro.
V Hug, G N Hortobagyi, B Drewinko, M Finders.
J Clin Oncol, 1985 Dec 01; 3(12). PMID: 4067614
Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database.
Gloria J Morris, Sashi Naidu, +8 authors, Edith P Mitchell.
Cancer, 2007 Jul 11; 110(4). PMID: 17620276
Highly Cited.
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.
Mothaffar F Rimawi, Ingrid A Mayer, +10 authors, Jenny C Chang.
J Clin Oncol, 2013 Apr 10; 31(14). PMID: 23569315    Free PMC article.
Highly Cited.
Palbociclib and Letrozole in Advanced Breast Cancer.
Richard S Finn, Miguel Martin, +12 authors, Dennis J Slamon.
N Engl J Med, 2016 Dec 14; 375(20). PMID: 27959613
Highly Cited.
Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial.
Gunter von Minckwitz, Sherko Kümmel, +11 authors, German Breast Group.
J Natl Cancer Inst, 2008 Apr 10; 100(8). PMID: 18398097
Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer.
Manfred Kaufmann, Gunter von Minckwitz, +16 authors, Lajos Pusztai.
Ann Surg Oncol, 2011 Dec 24; 19(5). PMID: 22193884
Highly Cited.
Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.
Antonio C Wolff, Ann A Lazar, +16 authors, Daniel F Hayes.
J Clin Oncol, 2012 Dec 13; 31(2). PMID: 23233719    Free PMC article.
Highly Cited.
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
Karen A Gelmon, Marc Tischkowitz, +11 authors, Amit Oza.
Lancet Oncol, 2011 Aug 25; 12(9). PMID: 21862407
Highly Cited.
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.
José Baselga, Ian Bradbury, +25 authors, NeoALTTO Study Team.
Lancet, 2012 Jan 20; 379(9816). PMID: 22257673    Free PMC article.
Highly Cited.
The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.
Mette S van Ramshorst, Margriet van der Heiden-van der Loo, +2 authors, Gabe S Sonke.
Breast Cancer Res Treat, 2016 Jul 01; 158(2). PMID: 27357813
Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.
Johnathan A Watkins, Sheeba Irshad, Anita Grigoriadis, Andrew N J Tutt.
Breast Cancer Res, 2014 Aug 06; 16(3). PMID: 25093514    Free PMC article.
Highly Cited. Review.
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.
Gunter von Minckwitz, Holger Eidtmann, +22 authors, Arbeitsgemeinschaft Gynäkologische Onkologie–Breast Study Groups.
N Engl J Med, 2012 Jan 27; 366(4). PMID: 22276820
Highly Cited.
Increase in response rate by prolonged treatment with neoadjuvant letrozole.
J Michael Dixon, Lorna Renshaw, +6 authors, William R Miller.
Breast Cancer Res Treat, 2008 Feb 12; 113(1). PMID: 18264759
Bevacizumab added to neoadjuvant chemotherapy for breast cancer.
Harry D Bear, Gong Tang, +17 authors, Norman Wolmark.
N Engl J Med, 2012 Jan 27; 366(4). PMID: 22276821    Free PMC article.
Highly Cited.
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
Nicholas C Turner, Jungsil Ro, +12 authors, PALOMA3 Study Group.
N Engl J Med, 2015 Jun 02; 373(3). PMID: 26030518
Highly Cited.
Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?
Karin Beelen, Wilbert Zwart, Sabine C Linn.
Nat Rev Clin Oncol, 2012 Jul 25; 9(9). PMID: 22825374
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.
Rita Nanda, Laura Q M Chow, +9 authors, Laurence Buisseret.
J Clin Oncol, 2016 May 04; 34(21). PMID: 27138582    Free PMC article.
Highly Cited.
Neoadjuvant Model for Testing Emerging Targeted Therapies in Breast Cancer.
Angela Esposito, Carmen Criscitiello, Giuseppe Curigliano.
J Natl Cancer Inst Monogr, 2015 Jun 13; 2015(51). PMID: 26063887
Weekly paclitaxel in the adjuvant treatment of breast cancer.
Joseph A Sparano, Molin Wang, +7 authors, Nancy E Davidson.
N Engl J Med, 2008 Apr 19; 358(16). PMID: 18420499    Free PMC article.
Highly Cited.
Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer.
Ana M Gonzalez-Angulo, Kirsten M Timms, +11 authors, Funda Meric-Bernstam.
Clin Cancer Res, 2011 Jan 15; 17(5). PMID: 21233401    Free PMC article.
Highly Cited.
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
Gunter von Minckwitz, Michael Untch, +14 authors, Sibylle Loibl.
J Clin Oncol, 2012 Apr 18; 30(15). PMID: 22508812
Highly Cited.
Comprehensive molecular portraits of human breast tumours.
Cancer Genome Atlas Network.
Nature, 2012 Sep 25; 490(7418). PMID: 23000897    Free PMC article.
Highly Cited.
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D J Slamon, B Leyland-Jones, +9 authors, L Norton.
N Engl J Med, 2001 Mar 15; 344(11). PMID: 11248153
Highly Cited.
Improving Response to Hormone Therapy in Breast Cancer: New Targets, New Therapeutic Options.
Hope S Rugo, Neelima Vidula, Cynthia Ma.
Am Soc Clin Oncol Educ Book, 2016 Jun 02; 35. PMID: 27249746
Adjuvant ovarian suppression in premenopausal breast cancer.
Prudence A Francis, Meredith M Regan, +28 authors, International Breast Cancer Study Group.
N Engl J Med, 2014 Dec 17; 372(5). PMID: 25495490    Free PMC article.
Highly Cited.
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
Marc L Citron, Donald A Berry, +18 authors, Larry Norton.
J Clin Oncol, 2003 Apr 02; 21(8). PMID: 12668651
Highly Cited.
NCCN Guidelines Insights: Breast Cancer, Version 1.2017.
William J Gradishar, Benjamin O Anderson, +30 authors, Rashmi Kumar.
J Natl Compr Canc Netw, 2017 Apr 14; 15(4). PMID: 28404755
Highly Cited.
BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years.
L Robertson, H Hanson, +14 authors, BCSC (UK).
Br J Cancer, 2012 Feb 16; 106(6). PMID: 22333603    Free PMC article.
Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study.
Edith A Perez, Carlos Barrios, +12 authors, Paul Ellis.
J Clin Oncol, 2017 Jan 06; 35(2). PMID: 28056202    Free PMC article.
Highly Cited.
Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy.
Ute E Krainick-Strobel, Werner Lichtenegger, +6 authors, Stefan Paepke.
BMC Cancer, 2008 Feb 28; 8. PMID: 18302747    Free PMC article.
Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01).
A Charehbili, S van de Ven, +18 authors, Dutch Breast Cancer Research Group (BOOG).
Ann Oncol, 2014 Mar 04; 25(5). PMID: 24585721
First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer.
Laleh Amiri-Kordestani, Suparna Wedam, +6 authors, Patricia Cortazar.
Clin Cancer Res, 2014 Sep 11; 20(21). PMID: 25204553
Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.
Norikazu Masuda, Yasuaki Sagara, +8 authors, Shinzaburo Noguchi.
Lancet Oncol, 2012 Jan 24; 13(4). PMID: 22265697
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
E Senkus, S Kyriakides, +6 authors, ESMO Guidelines Committee.
Ann Oncol, 2015 Sep 01; 26 Suppl 5. PMID: 26314782
Highly Cited.
Neoadjuvant Therapy in Breast Cancer as a Basis for Drug Approval.
Donald A Berry, Clifford A Hudis.
JAMA Oncol, 2015 Jul 17; 1(7). PMID: 26181139
Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry.
Katrina R Bauer, Monica Brown, +2 authors, Vincent Caggiano.
Cancer, 2007 Mar 28; 109(9). PMID: 17387718
Highly Cited.
Ertumaxomab: a trifunctional antibody for breast cancer treatment.
Philipp Kiewe, Eckhard Thiel.
Expert Opin Investig Drugs, 2008 Sep 24; 17(10). PMID: 18808314
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Richard S Finn, John P Crown, +15 authors, Dennis J Slamon.
Lancet Oncol, 2014 Dec 20; 16(1). PMID: 25524798
Highly Cited.
Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited.
Barbara Lupo, Livio Trusolino.
Biochim Biophys Acta, 2014 Jul 16; 1846(1). PMID: 25026313
Pathways to tamoxifen resistance.
Rebecca B Riggins, Randy S Schrecengost, Michael S Guerrero, Amy H Bouton.
Cancer Lett, 2007 May 04; 256(1). PMID: 17475399    Free PMC article.
Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens.
C K Osborne, L Kitten, C L Arteaga.
J Clin Oncol, 1989 Jun 01; 7(6). PMID: 2715802
Response-guided neoadjuvant chemotherapy for breast cancer.
Gunter von Minckwitz, Jens Uwe Blohmer, +16 authors, Sibylle Loibl.
J Clin Oncol, 2013 Sep 05; 31(29). PMID: 24002511
Highly Cited.
Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer.
Sven Rottenberg, Anders O H Nygren, +10 authors, Piet Borst.
Proc Natl Acad Sci U S A, 2007 Jul 13; 104(29). PMID: 17626183    Free PMC article.
Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.
Sherene Loi, Nicolas Sirtaine, +13 authors, Christos Sotiriou.
J Clin Oncol, 2013 Jan 24; 31(7). PMID: 23341518
Highly Cited.
Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation.
Leo A Niemeier, David J Dabbs, +2 authors, Rohit Bhargava.
Mod Pathol, 2009 Nov 10; 23(2). PMID: 19898421
Highly Cited.
Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).
D Mavroudis, E Saloustros, +7 authors, Breast Cancer Investigators of Hellenic Oncology Research Group (HORG), Athens, Greece.
Ann Oncol, 2015 May 04; 26(7). PMID: 25935793
Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing.
Priyanka Sharma, Jennifer R Klemp, +15 authors, Andrew K Godwin.
Breast Cancer Res Treat, 2014 May 09; 145(3). PMID: 24807107    Free PMC article.
HER3, serious partner in crime: therapeutic approaches and potential biomarkers for effect of HER3-targeting.
Arjan Kol, Anton G T Terwisscha van Scheltinga, +4 authors, Carolina P Schröder.
Pharmacol Ther, 2014 Feb 12; 143(1). PMID: 24513440
Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.
Priya Rastogi, Stewart J Anderson, +15 authors, Norman Wolmark.
J Clin Oncol, 2008 Feb 09; 26(5). PMID: 18258986
Highly Cited.
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
Jonathan A Ledermann, Philipp Harter, +15 authors, Ursula Matulonis.
Lancet Oncol, 2016 Sep 13; 17(11). PMID: 27617661
Highly Cited.
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Joyce O'Shaughnessy, David Miles, +11 authors, Robert Leonard.
J Clin Oncol, 2002 Jun 18; 20(12). PMID: 12065558
Highly Cited.
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.
Hope S Rugo, Olufunmilayo I Olopade, +41 authors, I-SPY 2 Investigators.
N Engl J Med, 2016 Jul 15; 375(1). PMID: 27406347    Free PMC article.
Highly Cited.
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Arlene Chan, Suzette Delaloge, +28 authors, ExteNET Study Group.
Lancet Oncol, 2016 Feb 15; 17(3). PMID: 26874901
Highly Cited.
PD-L1 expression is increased in a subset of basal type breast cancer cells.
Hatem Soliman, Farah Khalil, Scott Antonia.
PLoS One, 2014 Feb 20; 9(2). PMID: 24551119    Free PMC article.
Highly Cited.
Mechanisms of endocrine resistance in breast cancer.
C Kent Osborne, Rachel Schiff.
Annu Rev Med, 2010 Oct 05; 62. PMID: 20887199    Free PMC article.
Highly Cited. Review.
Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer.
G Allevi, C Strina, +15 authors, D Generali.
Br J Cancer, 2013 Apr 13; 108(8). PMID: 23579222    Free PMC article.
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Hannah Farmer, Nuala McCabe, +11 authors, Alan Ashworth.
Nature, 2005 Apr 15; 434(7035). PMID: 15829967
Highly Cited.
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 May 17; 365(9472). PMID: 15894097
Highly Cited.
Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer.
Teemu T Junttila, Guangmin Li, +2 authors, Mark X Sliwkowski.
Breast Cancer Res Treat, 2010 Aug 24; 128(2). PMID: 20730488
Highly Cited.
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
Antonio C Wolff, M Elizabeth H Hammond, +19 authors, College of American Pathologists.
J Clin Oncol, 2013 Oct 09; 31(31). PMID: 24101045
Highly Cited.
Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial.
Wolfgang Eiermann, Tadeusz Pienkowski, +15 authors, John R Mackey.
J Clin Oncol, 2011 Sep 14; 29(29). PMID: 21911726
Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen.
Anthony Kong, Daniel Rea, +11 authors, Soo-Chin Lee.
Oncotarget, 2016 Oct 23; 7(25). PMID: 27129177    Free PMC article.
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
Melinda L Telli, Kirsten M Timms, +22 authors, Andrea L Richardson.
Clin Cancer Res, 2016 Mar 10; 22(15). PMID: 26957554    Free PMC article.
Highly Cited.
Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
Sara A Hurvitz, Luc Dirix, +9 authors, Edith A Perez.
J Clin Oncol, 2013 Feb 06; 31(9). PMID: 23382472
Highly Cited.
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†.
G von Minckwitz, S Loibl, +145 authors, R Schlag.
Ann Oncol, 2014 Sep 17; 25(12). PMID: 25223482
Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer.
Stefania Mantarro, Marta Rossi, +5 authors, Lorenzo Moja.
Intern Emerg Med, 2015 Dec 30; 11(1). PMID: 26712595
Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group.
Amye J Tevaarwerk, Molin Wang, +9 authors, Nicholas J Robert.
J Clin Oncol, 2014 Oct 29; 32(35). PMID: 25349302    Free PMC article.
PD-L1 expression in triple-negative breast cancer.
Elizabeth A Mittendorf, Anne V Philips, +14 authors, Gheath Alatrash.
Cancer Immunol Res, 2014 Apr 26; 2(4). PMID: 24764583    Free PMC article.
Highly Cited.
Triple-negative breast cancer: clinical features and patterns of recurrence.
Rebecca Dent, Maureen Trudeau, +7 authors, Steven A Narod.
Clin Cancer Res, 2007 Aug 03; 13(15 Pt 1). PMID: 17671126
Highly Cited.
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.
David Cameron, Julia Brown, +22 authors, Richard Bell.
Lancet Oncol, 2013 Aug 13; 14(10). PMID: 23932548
Highly Cited.
Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study.
Thomas Bachelot, Céline Bourgier, +11 authors, Eric Pujade-Lauraine.
J Clin Oncol, 2012 May 09; 30(22). PMID: 22565002
Highly Cited.
Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.
Martine Piccart-Gebhart, Eileen Holmes, +32 authors, Edith A Perez.
J Clin Oncol, 2015 Nov 26; 34(10). PMID: 26598744    Free PMC article.
Highly Cited.
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.
Evandro de Azambuja, Andrew P Holmes, +24 authors, José Baselga.
Lancet Oncol, 2014 Aug 19; 15(10). PMID: 25130998
Highly Cited.
A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer.
Komal Jhaveri, Sarat Chandarlapaty, +18 authors, Shanu Modi.
Clin Breast Cancer, 2014 Feb 12; 14(3). PMID: 24512858
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
T Sørlie, C M Perou, +14 authors, A L Børresen-Dale.
Proc Natl Acad Sci U S A, 2001 Sep 13; 98(19). PMID: 11553815    Free PMC article.
Highly Cited.
Trastuzumab emtansine (T-DM1): a novel agent for targeting HER2+ breast cancer.
Howard A Burris, Jay Tibbitts, +2 authors, Gail D Lewis Phillips.
Clin Breast Cancer, 2011 Jul 07; 11(5). PMID: 21729661
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
André Robidoux, Gong Tang, +17 authors, Norman Wolmark.
Lancet Oncol, 2013 Oct 08; 14(12). PMID: 24095300
Highly Cited.
The relationship between the roles of BRCA genes in DNA repair and cancer predisposition.
Andrew Tutt, Alan Ashworth.
Trends Mol Med, 2002 Dec 10; 8(12). PMID: 12470990
Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer.
Carol A Lange, Douglas Yee.
Endocr Relat Cancer, 2011 May 27; 18(4). PMID: 21613412    Free PMC article.
Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers.
S Sjögren, M Inganäs, +2 authors, J Bergh.
J Clin Oncol, 1998 Feb 20; 16(2). PMID: 9469329
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).
William M Sikov, Donald A Berry, +14 authors, Eric P Winer.
J Clin Oncol, 2014 Aug 06; 33(1). PMID: 25092775    Free PMC article.
Highly Cited.
Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer.
Holbrook E Kohrt, Roch Houot, +11 authors, Ronald Levy.
J Clin Invest, 2012 Feb 14; 122(3). PMID: 22326955    Free PMC article.
Highly Cited.
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.
Heikki Joensuu, Pirkko-Liisa Kellokumpu-Lehtinen, +22 authors, FinHer Study Investigators.
N Engl J Med, 2006 Feb 24; 354(8). PMID: 16495393
Highly Cited.
Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.
Neil L Spector, Kimberly L Blackwell.
J Clin Oncol, 2009 Nov 04; 27(34). PMID: 19884552
Highly Cited. Review.
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
Lisa A Carey, Charles M Perou, +14 authors, Robert C Millikan.
JAMA, 2006 Jun 08; 295(21). PMID: 16757721
Highly Cited.
Mechanisms of aromatase inhibitor resistance.
Cynthia X Ma, Tomás Reinert, Izabela Chmielewska, Matthew J Ellis.
Nat Rev Cancer, 2015 Apr 25; 15(5). PMID: 25907219
Highly Cited. Review.
Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study.
Laura C Collins, Kimberly S Cole, +3 authors, Rulla M Tamimi.
Mod Pathol, 2011 May 10; 24(7). PMID: 21552212    Free PMC article.
Highly Cited.
Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy.
E H Lips, L Mulder, +6 authors, S Rodenhuis.
Ann Oncol, 2010 Oct 13; 22(4). PMID: 20937646
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +28 authors, George W Sledge.
N Engl J Med, 2015 Sep 29; 373(21). PMID: 26412349    Free PMC article.
Highly Cited.
Radiomics in Oncological PET/CT: Clinical Applications.
Jeong Won Lee, Sang Mi Lee.
Nucl Med Mol Imaging, 2018 Jun 27; 52(3). PMID: 29942396    Free PMC article.
Exposure to alendronate is associated with a lower risk of bone metastases in osteoporotic women with early breast cancer.
Vanessa Rouach, Inbal Goldshtein, +5 authors, Daniel Cohen.
J Bone Oncol, 2018 Aug 28; 12. PMID: 30148062    Free PMC article.
Tumor ablation using novel photothermal NaxWO3 nanoparticles against breast cancer osteolytic bone metastasis.
Shuo Jie, Xiaoning Guo, Zhengxiao Ouyang.
Int J Nanomedicine, 2019 Oct 02; 14. PMID: 31571856    Free PMC article.
Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy.
Xia Yang, Jia Rao, Wentao Yang, Ruohong Shui.
Target Oncol, 2018 Nov 09; 13(6). PMID: 30406444    Free PMC article.
Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer.
Robert Wesolowski, Andrew Stiff, +19 authors, William E Carson.
BMC Cancer, 2020 May 21; 20(1). PMID: 32429929    Free PMC article.
Engagement in an Interactive App for Symptom Self-Management during Treatment in Patients With Breast or Prostate Cancer: Mixed Methods Study.
Marie-Therése Crafoord, Maria Fjell, +2 authors, Ann Langius-Eklöf.
J Med Internet Res, 2020 Jul 15; 22(8). PMID: 32663140    Free PMC article.
Perioperative immunotherapy for muscle-invasive bladder cancer.
In-Ho Kim, Hyo Jin Lee.
Transl Androl Urol, 2021 Jan 19; 9(6). PMID: 33457270    Free PMC article.
Association of relative dose intensity with BMI and pathologic complete response in patients treated with neoadjuvant chemotherapy for breast cancer.
Ilana Usiskin, Fangyong Li, +2 authors, Tara Sanft.
Breast Cancer Res Treat, 2020 Oct 31; 186(1). PMID: 33125620
Current management of melanoma patients with nodal metastases.
Dale Han, Alexander C J van Akkooi, +5 authors, Douglas Reintgen.
Clin Exp Metastasis, 2021 May 08;. PMID: 33961168    Free PMC article.